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Coagulation cascadeAmyloid-β (Aβ) peptides are intimately involved in the inﬂammatory pathology of atherosclerotic vascular
disease (AVD) and Alzheimer's disease (AD). Although substantial amounts of these peptides are produced in
the periphery, their role and signiﬁcance to vascular disease outside the brain requires further investigation.
Amyloid-β peptides present in the walls of human aorta atherosclerotic lesions as well as activated and non-
activated human platelets were isolated using sequential size-exclusion columns and HPLC reverse-phase
methods. The Aβ peptide isolates were quantiﬁed by ELISA and structurally analyzed using MALDI-TOF mass
spectrometry procedures. Our experiments revealed that both aorta and platelets contained Aβ peptides,
predominately Aβ40. The source of the Aβ pool in aortic atherosclerosis lesions is probably the activated
platelets and/or vascular wall cells expressing APP/PN2. Signiﬁcant levels of Aβ42 are present in the plasma,
suggesting that this reservoir makes a minor contribution to atherosclerotic plaques. Our data reveal that
although aortic atherosclerosis and AD cerebrovascular amyloidosis exhibit clearly divergent end-stage
manifestations, both vascular diseases share some key pathophysiological promoting elements and pathways.
Whether they happen to be deposited in vessels of the central nervous system or atherosclerotic plaques in
the periphery, Aβ peptides may promote and perhaps synergize chronic inﬂammatory processes which
culminate in the degeneration, malfunction and ultimate destruction of arterial walls.se; ApoE, apolipoprotein E; APP,
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Numerous studies have demonstrated that amyloid-beta (Aβ)
peptides have a central role in the pathogenesis of Alzheimer's disease
(AD) and recent evidence derived from epidemiologic, correlative and
experimental data has strongly linked intracranial atherosclerotic
vascular disease (AVD) with the pathogenesis of AD [1–3]. The
Baltimore longitudinal study on aging suggests that the presence of
intracranial AVD signiﬁcantly increases the odds of dementia, indepen-dent of cerebral infarction [4]. Multiple established risk factors for AVD
have also been recognized to be risk factors for the development of AD
(reviewed in [5,6]). Clinical investigations have reported that coronary
artery disease, myocardial infarction, carotid artery disease, peripheral
artery disease, hypertension, diabetes mellitus, cigarette smoking and
obesity are all more common in subjects with AD (reviewed in [2]).
Longitudinal and twin studies have reinforced the tenet of cardiovas-
cular failure and AVD, in the absence of stroke, as risk factors for AD in
carriers of the apolipoprotein E (ApoE) ε4 allele [7]. Moreover, the
association between cardiovascular disease and dementia is not
explained by genetic or early life environmental factors common in
both disorders [7]. Individuals with midlife hyperlipidemia have an
elevated risk of developing AD, and individuals with clinically or
neuropathologically diagnosed AD have higher blood cholesterol levels
compared to non-demented controls [8–10]. Considerable evidence
from experimental studies links cholesterol to Aβmetabolism [11,12].
Both AD and AVD evolve in an intensely inﬂammatory milieu
[13–19] that ultimately destroys brain and vascular tissues. In AD,
Aβ accumulation induces microvascular inﬂammation mediated by
Fig. 1. Representative human aorta atherosclerotic lesions. A) An example of the
advanced aortic atherosclerotic lesions used in this study demonstrating lipid cores
with areas of calciﬁcation underlying the ﬁbrous cap. B) Complicated atherosclerotic
lesions with ulceration and rupture of the ﬁbrous caps showing areas of thrombosis.
E=endothelium; FC=ﬁbrous cap; LC=lipid cores; C=areas of calciﬁcation;
M=tunica media; A=adventitia; T=thrombosis; UFC=ulcerated (crater-like)
ﬁbrous cap.
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myocytes and pericytes [20–23]. Under normal and pathological
conditions, the Aβ peptides play an important role in the modulation
of inﬂammation [24,25]. In addition, pathological interactions be-
tween molecules of the coagulation cascade and Aβ have been shown
to alter thrombosis and ﬁbrinolysis thus establishing associations
among atherosclerosis, thrombosis, cerebral amyloid angiopathy
(CAA), brain hypoperfusion and AD [26]. The amyloidogenic 40/42
amino acid-long Aβ peptides are derived, by the proteolytic action of
the β- and γ-secretases, from larger amyloid-beta precursor proteins
that are 695, 751 and 770 amino acids in length (APP695, APP751 and
APP770). Large amounts of Aβ peptides deposited in the brain
microvascular walls result in considerable pathophysiological alter-
ations, and the severity of cognitive decline is associatedwith thedegree
of CAA and arteriosclerosis/lipohyalinosis [27]. In particular, the
capillary deposition of Aβ42 is highly correlated with AD pathology
[28], blood–brain barrier (BBB) disruptions and severe alterations in
brain perfusion [13,29–31].
The Aβ peptides are generated in appreciable quantities outside of
the central nervous system in places such as the neuromuscular
junctions of skeletal muscle ﬁbers [32] and in the α-granules of
platelets [33] that contribute to the pool of Aβ in the circulation. Other
potential sources of APP/Aβ are the endothelial cells of the vasa
vasorum that invade and feed the walls of the atherosclerotic lesion
[34]. In platelets, the Aβ peptides are mainly derived from the APP751
and APP770, known as protease nexin-2 (PN2), which carries a Kunitz
(serine) protease inhibitory (KPI) domain. The APP/PN2 molecule has
important functions in the coagulation cascade as it acts as an
inhibitory component of factors, IXa, Xa, XIa and tissue factor VIIa
complex [35–38], thus modulating hemostasis following vascular injury
by limiting thrombosis [39]. In a strainof transgenicmice (Tg-rPF4/βAPP)
that over-express the APP/PN2, the thrombotic-capacity is diminished
and the extent of cerebral hemorrhage is increased accordingly [39].
Activated platelets participate in the pathogenesis and evolution of
atherosclerosis due to a strong contribution in the development of
inﬂammatory responses in leukocytes, endothelial cells and vascular
myocytes [40–42]. The prothrombotic interactions between platelets
and vascular wall cells contribute to the establishment of the
atheromatous lesions from their early stages to the ﬁnal plaque rupture
and thrombosis (reviewed in [43]). The elegant immunocytochemical
and electron microscopic studies of De Meyer and colleagues clearly
demonstrated the presence of APP and Aβ within platelets that were
phagocytized by macrophages in areas of neovascularization in
advanced atherosclerotic lesions [34]. The biochemical characterization
of Aβ peptides presented in this study is complementary to these
meticulous histological investigations. Although platelets and circulat-
ing Aβ may be a signiﬁcant source of these peptides in the
atherosclerotic lesions, it is possible that the Aβ peptides also originate,
under pathological conditions, from the arterial tunica media myocytes
and endothelial cells that also express APP [44].
In the present investigation we quantiﬁed, chromatographically
isolated and characterized by mass spectrometry the Aβ peptides
present in the walls of human atherosclerotic aortas. We also
investigated the chemical characteristics of the Aβ peptides by mass
spectrometry in freshly isolated inactivated and activated platelets as
a possible source of the Aβ found in atherosclerotic lesions. In
addition, we discuss the possible source of atherosclerotic Aβ as well
as the potential relevance of Aβ pro-inﬂammatory activity to vascular
pathology in the context of both AVD and AD.
2. Materials and methods
2.1. Thoracic aortas
Thoracic aortic sections (2.5 g each) exhibiting severe atheroscle-
rotic lesions were obtained in the immediate postmortem from 6Caucasian individuals with a mean age of 84 years. There were 3
female and 3 male subjects, 4 of whom were demented with AD and
one with Parkinsonian dementia. One subject, a 92 year-oldmale, was
non-demented. The aortas exhibited severe regions of calciﬁcation
complicated by ulcerations, intramural hemorrhages, rupture of
ﬁbrous caps and thrombosis as shown in Fig. 1.2.2. Extraction of Aβ peptides from aortas
The aortic sections were thoroughly rinsed with cold deionized
water to remove all traces of blood, and the adventitial connective
tissue was detached and discarded. The intima/media of aortic
sections were pooled and ﬁnelyminced and ground in liquid nitrogen.
Half of the pulverized tissue was placed in a beaker with 20 ml of 98%
glass-distilled formic acid (GDFA), stirred overnight at 4 °C and
centrifuged at 250,000×g for 1 h at 4 °C. The acid-soluble phase
between the ﬂoating fatty layer and the bottom pellet was collected
and remaining solids were removed by gravimetric ﬁltration using
Whatman #1 ﬁlter paper. The ﬁltrate was centrifuged a second time
and the acid-soluble fraction divided into 500 μl aliquots which were
submitted to fast protein liquid chromatography (FPLC). The second
half of the pulverized aortic tissue was suspended in 400 ml of 0.1 M
ammonium bicarbonate and 0.01% sodium azide and stirred overnight
at 4 °C. The suspension was centrifuged at 30,000×g for 1 h at 4 °C.
The supernatant (water-soluble fraction) was ﬁltered through a
45 μm nylon mesh, freeze-dried and lyophilized. Fifty mg aliquots of
the lyophilized water-soluble fractionwere then dissolved in 500 μl of
80% GDFA and submitted to FPLC.
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Both acid-soluble fractions and water-soluble fractions were
separated by size-exclusion FPLC on a pre-calibrated 1 cm×30 cm
Superose 12 column (Pharmacia-Amersham-GE, Uppsala, Sweden).
The column was equilibrated and developed with 80% GDFA at a ﬂow
rate of 15 ml/h at room temperature (RT) and absorbance monitored
at 280 nm. The fractions containing 2–10 kDa molecules were
collected and the volume reduced by vacuum centrifugation (Savant,
Farmingdale, NY). To enrich the Aβ peptides and eliminatemost of the
ﬂanking contaminations, 3 runs of the 2–10 kDa chromatographic
eluants were pooled and re-chromatographed under the same
conditions as described above.
To further purify the Aβ peptides, both the acid-soluble andwater-
soluble fractions obtained by size-exclusion FPLC were reduced to
100 μl and submitted to high performance liquid chromatography
(HPLC, Thermo Separation Products, Waltham, MA) on a Synchropak
GPC-peptide size-exclusion 7.8 cm×90 cm column (Synchrom Inc.
Lafayette, IN). The chromatographies were conducted at RT using 80%
GDFA at a ﬂow rate of 0.2 ml/min and the eluate absorbance was
monitored at 280 nm. Western blots, using antibodies against Aβ40
and Aβ42, were employed to localize the Aβ peptide-containing
fractions. The Aβ fraction from three column runs was pooled, the
volume reduced to 500 μl and injected into an HPLC reverse-phase C8
semi-preparative 9.4 cm×25 cm column (Zorbax 300 SB/5 μm beads;
Wilmington, DE). The chromatography was developed using an
elution gradient from 20% to 60% acetonitrile in water containing
0.1% triﬂuoroacetic acid (TFA) with a ﬂow rate of 1.5 ml/min, at 80 °C.
Eluate absorbance was monitored at 214 nm. For identiﬁcation of the
Aβ peptide-containing fractions, the specimens were reduced in
volume and submitted to Western blot analysis.
2.4. Analysis of Aβ peptides from inactivated and activated
human platelets
Fresh platelets were obtained from 5 separate American Red Cross
volunteer donors by platelet-pheresis and immediately processed
following the procedures published by Li et al. [33,45] with modiﬁca-
tions. A complete description of the technical details has been previously
published by our group [46]. Both inactivated and thrombin-collagen
activated platelets were submitted to FPLC (Superose 12), HPLC
(Synchropak GPC-peptide) and reverse-phase HPLC (Zorbax 300 SB)
as described above for the aortic tissue.
2.5. Western blots analysis of Aβ peptides
Samples from the HPLC, representing the total fractionation runs,
were assessed for the presence of Aβ40 and Aβ42 peptides
(Invitrogen, Carlsbad CA) using Western blots as described before
[47].
2.6. Identiﬁcation of Aβ peptides by MALDI-TOF mass spectrometry
A matrix assisted laser desorption ionization-time of ﬂight
(MALDI-TOF) Voyager DE STR mass spectrometer (Applied Biosys-
tems, Foster City, CA) was employed to obtain data from the HPLC
fractions. The applied Biosystems CalMix-2 was used as calibration
mixture. The detailed protocol and composition of the calibration
markers was previously published [48].
3. Results
3.1. Atherosclerotic aorta analyses
Our speciﬁc experimental goal was to establish the chemical
characteristics of Aβ peptides in atherosclerotic aortic walls and ininactivated and activated platelets. Aortic vessels of elderly in-
dividuals with severe atherosclerotic lesions showed that the Aβ40
peptide was on the average 100 times more abundant than Aβ42:
75 ng/g of tissue and 0.7 ng/g of tissue, respectively [46]. MALDI-TOF
mass spectrometric analysis of both the water-soluble and acid-
soluble aortic fractions, that were submitted to sequential steps of
FPLC and HPLC reverse-phase column separations (Fig. 2A–D),
revealed the presence of Aβ peptides with N-termini beginning at
residues 1 through 5 and with C-termini ending at residues 39, 40, 41,
42 and 43 (Table 1). In addition, elongated Aβ peptides, extending
from residues 1 to 48 (Aβ sequence numbering), were detected in
peak 7 of the HPLC C3 reverse-phase column water-soluble fraction
(Fig. 2D). This peptide could result from γ-secretase cleavage close to
APP ε-site, which corresponds in the Aβ sequence to residue 49.
Western blot analyses of the reverse-phase column fractions did not
show the presence of signiﬁcant amounts of Aβ42 possibly due to the
comparatively low values of this peptide as detected by immunoassay.
3.2. Platelet analyses
Immunoassay analysis revealed that the inactivated platelets had
an average of 84 ng/g tissue of Aβ40 and activated platelets contained
an average of 57 ng/g tissue, while in both cases there were very low
levels of Aβ42: 1.6 ng/g tissue and 1.7 ng/g tissue, respectively [46].
The Aβ42 in the platelets, whether activated or inactivated, represents
only 2–3% of the Aβ40 values, closely mimicking the values observed
for the atherosclerotic aorta [46]. In agreement with these low Aβ42
values, we did not observe Aβ42 in the chromatographic fractions of
the aorta (Fig. 2D) or inactivated platelets by Western blotting
(Fig. 3A), but this peptide was found in the activated platelets
(Fig. 3B). Using size-exclusion FPLC and reverse-phase HPLC, the
inactivated (Fig. 3A) and (Fig. 3B) activated platelet Aβ peptides were
independently enriched and subsequently characterized by MALDI-
TOF mass spectrometry (Table 2). Mass spectrometry of inactivated
platelets chromatographic fractions conﬁrmed the absence of Aβ42,
while in the activated platelets, this peptide species was present,
theoretically corresponding to peptide Aβ6-42 (Table 2). Intriguingly,
the total Aβ value in the inactivated platelets is 30% higher than in the
activated platelets [46]. A possible explanation is that aggregated Aβ
becomes undetectable by the immunoassay or alternatively that upon
degranulation of platelets, the Aβ was immunologically hindered by
interaction with platelet-released ﬁbrinogen [26]. Alternatively, any
excess of free Aβ in the circulationwill be complexedwith albumin for
which Aβ has a very high afﬁnity [49–51]. Mass spectrometry showed
that activated platelet Aβ peptides included species starting at
residues 1, 2, 3, 4, 5 and 6, with C-termini at residues 37 through 42
(Table 2). The degraded N-terminal Aβ sequences in platelets and in
atherosclerotic vessels are very similar to those observed in the brains
of AD subjects [52,53].
4. Discussion
The atherosclerotic aortas contained Aβ peptides composed
primarily of the Aβ40 species [46]. The Aβ peptides may have been
produced at the site of the lesions by myocytes, endothelial cells
[54,55] or platelets [33,34]. The preponderance of Aβ40 species in the
vascular lesions may simply reﬂect the greater solubility and mobility
of this peptide. Immunoassay studies demonstrate that signiﬁcant
levels of Aβ42 are found in plasma [46,49], while in the aorta this
peptide species is less represented [46], suggesting that the plasma
Aβ42 is not the dominant contributor to atherosclerotic plaques. Little
is known about the catabolic fate of the Aβ peptides generated in
skeletal muscle, a tissue composing about one third of the total body
mass. The post-synaptic domain of the skeletal muscle cholinergic
neuromuscular junctions contains APP and Aβ peptides [56]. The Aβ
peptidesmay be degradedmainly in themuscle itself, but it is possible
Table 1
Mass spectrometric analyses of the water-soluble and formic acid-soluble aortic Aβ
peptides.
Peak Mass observed Mass calculated Peptide fragment Modiﬁcation
Aorta acid soluble
5 4287.89 4287.77 1–39 2 F
5 4330.24 4330.91 1–40 –
5 4399.66 4400.06 2–42 –
5 4529.57 4529.17 2–43 F
6 4514.41 4515.15 1–42 –
6 3981.14 3981.6 5–41 –
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The skeletalmuscles contain a higher ratio of Aβ42 [57] and analogous
proportions of this molecule are not observed in aortic walls. Based on
the tissue ratios of Aβ40:Aβ42, the experimental observations
suggest that the Aβ contributions by plasma, brain or muscle to the
atherosclerotic lesions may be minimal. Measurements of Aβ40
and Aβ42 in activated and inactivated platelets revealed that Aβ40
was the dominant peptide, similar to the values observed for the
atherosclerotic aorta [46]. Therefore, judging from the relative
amounts of Aβ40 and Aβ42 it could be suggested that the Aβ peptidesAorta water soluble
4 4259.37 4259.77 1–39 F
4 4374.36 4374.91 1–40 F+O
4 4487.59 4488.07 1–41 F+O
4 4259.37 4259.82 2–40 F+O
5 4531.37 4531.14 1–42 O
5 4547.38 4547.15 1–42 2 O
5 4643.42 4644.26 1–43 F
5 4243.06 4243.82 2–40 F
5 4516.30 4517.17 2–43 O
5 4243.06 4243.86 4–42 F+O
5 4332.14 4332.97 4–43 2 O
6 4444.67 4444.07 1–41 —
6 4516.29 4515.15 1–42 —
6 4356.53 4356.98 2–41 F
6 4444.67 4444.06 2–42 F+O
6 4311.59 4310.98 3–42 PG
6 4356.53 4356.98 3–42 F
6 4356.53 4356.97 4–43 2 F
7 4516.23 4515.15 1–42 −
7 5158.29 5157.96 1–48 O
The Mr deviation between the calculated and observed Aβ related peptides in all
instances is less than ±1 Da. Post-translational modiﬁcations: O=oxidation;
F=formylation; PG=pyroglutamyl.present in the atherosclerotic lesions mainly originate from activated
platelets.
The α-granules of platelets are considered the major source of
circulating APP/PN2 and of Aβ [33,45]. The relentless vascular wall
damage that accompanies atherosclerosis and concomitant reduced
ability to repair are phenomena inherent to aging-associated vascular
deterioration. These events favor increased platelet activation that is
mostly mediated by local secretion of tissue factor VIIa and exposure to
the von Willebrand factor [58,59]. Thus, platelets carrying APP/PN-2
are abundantly available in areas of vascular injury as they participate in
the coagulation cascade. In the atherosclerotic lesions, activated
macrophages contain endocytic vesicles loaded with platelets and Aβ
peptides [34]. A body of evidence reveals a pathological correlation
between AVD, AD and CAA [3,5,13,14,60] probably mediated by
sustained arterial wall injury that elicits, in all of these conditions,
chronic vascular and brain inﬂammation. In addition to the putative
platelet-atherosclerotic-linked Aβ source, the Aβ peptides in the
atherosclerotic plaques may also be directly derived from the arterialFig. 2. Chromatographic proﬁles of aortic atherosclerotic wall. A) FPLC Superose 12 size-
exclusion proﬁle (solid line trace) of the whole aorta pulverized in liquid nitrogen and
extracted with ammonium bicarbonate. The specimens containing the 2–10 kDa
molecules (48–62 min, solid bar) were collected and re-chromatographed under the
same conditions to enrich the Aβ-containing fractions (hyphened trace). B) FPLC
Superose 12 size-exclusion chromatographic traces of the whole aorta pulverized in
liquid nitrogen and extracted with GDFA. The continuous line represents the proﬁle of
the initial GDFA-soluble fraction. The eluants, collected from 2 of these chromatogra-
phies containing the 2–10 kDa, were pooled, concentrated and re-chromatographed
under the same conditions (hyphened line trace). C) Size-exclusion HPLC (GPC-Protein
column) proﬁles of both water and GDFA fractions collected in A and B, respectively.
Western blot (data not shown) demonstrated the Aβ peptides were contained in the
ﬁrst peak (indicated by bar). D) Reverse-phase HPLC proﬁles of the Aβ-containing
peaks shown in C. The fractions containing the Aβ peptides were detected by Western
blot (insert). Only the Aβ peptides ending at residue 40 were detected in both the
water-soluble and acid-soluble fractions. The standards correspond to monomeric (m)
and dimeric (d) Aβ1-40.
Fig. 3. Reverse-phase HPLC proﬁles and Aβ Western blots of human platelets.
A) Resting platelets were lysed in GDFA and the acid-soluble fraction submitted to
Superose 12 FPLC and Synchropak-GPC peptide HPLC fractionation. The fractions
containing the Aβ peptides were further puriﬁed by C8 reverse-phase. Fractions 11–
14 contained Aβ ending in residue 40. B) Amyloid-β peptides in activated platelets
(see Methods section) were chromatographically enriched as described in A. The
trace shows the HPLC C8 reverse-phase elution proﬁle. Fractions 9–12 contain the
Aβ peptides ending in residue 40 (see insert). Aβ42 was also observed by Western
blot in peak 8 and conﬁrmed by mass spectrometry. In both A and B, the standards
correspond to monomeric (m) and dimeric (d) Aβ1-40/42 and the diagonal line
indicates the acetonitrile gradient concentration.
Table 2
Mass spectrometric analyses of the water-soluble and formic acid-soluble activated and
inactivated platelets.
Peak Mass observed Mass calculated Peptide fragment Modiﬁcation
Inactivated platelets
11 3915.98 3915.43 4–39 —
12 3943.05 3943.43 4–39 F
12 4030.02 4030.57 4–40 O
12 3882.05 3883.39 5–40 O
13 4043.96 4044.5 2–38 F
13 4043.96 4044.55 3–39 —
14 4028.95 4030.57 4–40 O
15 4070.55 4070.57 4–40 2 F
15 3925.36 3923.39 5–40 2 F
Activated platelets
Peak Mass observed Mass calculated Peptide fragment Modiﬁcation
8 4498.48 4499.01 1–41 2 F
8 4070.45 4070.57 4–40 2 F
8 3895.73 3895.39 5–40 F
8 3895.73 3895.44 6–42 –
9 4269.94 4270.76 2–40 2 F
9 3976.77 3977.42 3–38 O
9 4099.60 4100.55 3–39 2 F
9 4071.24 4070.57 4–40 2 F
9 3883.26 3883.39 5–40 O
10 4016.56 4016.50 2–38 –
10 4072.13 4072.55 3–39 F
10 3883.69 3883.39 5–40 O
11 4072.07 4072.50 2–38 2 F
11 4072.07 4072.55 3–39 F
11 3883.96 3883.39 5–40 O
12 3975.80 3975.44 2–37 O
12 4071.03 4070.57 4–40 2 F
12 3882.80 3883.39 5–40 O
The Mr deviation between the calculated and observed Aβ related peptides in all
instances is less than ±1 Da. Post-translational modiﬁcations: O=oxidation;
F=formylation.
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with a KPI domain [61].
The presence of Aβ peptides in atherosclerotic plaques may
synergistically increase the chronic inﬂammatory processes that
sustain the degeneration and destruction of the arterial walls.
Addition of human platelets to human and rodent macrophages in
culture results in phagocytosis with induction of iNOS and foam cell
formation [34]. Furthermore, in the atherosclerotic lesions, macro-
phage activation is triggered by, among other eliciting mechanisms,
Aβ peptides that stimulate the production of iNOS and COX-2 [34]. A
focal vascular inﬂammatory response in the vulnerable region of
atheroma plaques may contribute to plaque instability and rupture
[34]. A potent pro-inﬂammatory capacity of the Aβ peptides has been
mechanistically demonstrated. The amino acid sequence of Aβ His-
His-Gln-Lys, corresponding to residues 13–16, binds to heparan
sulfate proteoglycans on the surface of macrophage microglia in the
brain, inducing these cells to kill neurons [24,25]. In in vivo
competition experiments, administration of this synthetic peptide
suppressed Aβ-induced inﬂammation in the rat cerebral cortex [25].
Likewise, suppression of microglial synthesis of glycosaminoglycans
or degradation of glycosaminoglycans also blocked activation of
microglia and prevented neuronal demise [25]. We have previously
shown that Aβ elicits the differentiation of monocytes into macro-phages and induces the secretion of inﬂammation-related cytokines
and chemokines [62]. Moreover, in a model of the BBB when Aβ is
present on the brain side, it promotes monocyte/macrophage
migration across the blood–brain barrier [62]. Vascular inﬂammation
in AVD has traditionally been thought to be limited to large and
medium-sized arteries, but recent work indicates that the systemic
microvasculature is also affected [63–67] probably due to increased
circulating concentrations of inﬂammatory mediators. In elderly
humans, elevated serum C-reactive protein concentrations correlate
with vascular inﬂammation and atherosclerosis, and with markers of
brain microvascular inﬂammation in AD [68,69].
Hemostasis abnormalities such as increased activated factor VIIa
and von Willebrand factor have been reported in AD [59]. Elevated
platelet membrane ﬂuidity [70], disturbances in protein kinase C [71]
and in phospholipases C [72], and abnormal platelet activation [58] as
well as increased serum levels of thrombomodulin and E-selectin [73]
have also been observed in AD. In addition to the macrophage-
mediated vascular inﬂammatory reactions, a second mechanism
appears to link hemostasis with cerebrovascular amyloidosis. With
advancing age the incidence of endothelial injury increases and the
ability to repair decreases. This relentless emerging situation
ultimately enhances APP/PN-2 production in platelets and vascular
walls thereby contributing to a local reduction of hemostatic activity
that favors production of cerebrovascular microhemorrhages [74,75].
5. Conclusions
Atherosclerotic vascular disease and AD cerebrovascular amyloid-
osis, despite their different end-stage manifestations, share pathophys-
iological pathways. Our studies demonstrate that the atherosclerotic
lesions, common in elderly individuals, contain a heterogeneous
1513T.A. Kokjohn et al. / Biochimica et Biophysica Acta 1812 (2011) 1508–1514mixture of Aβ peptides. Immunoassays suggest a preponderance of the
shorter Aβ40 over Aβ42. Most likely the sources of these Aβ peptides
are the cells of the vascular walls that express APP/PN2/Aβ and the
platelets that participate in the atherosclerotic inﬂammatory and
disturbed coagulation cascades inherent to chronic arterial wall
degeneration. The increased and persistent synthesis of proinﬂamma-
tory-related molecules by activated macrophages/microglia and acti-
vated platelets are, in part, mediated by the presence of Aβ peptides. In
both AVD and AD, the Aβ peptides appear to contribute to the
inﬂammatory reactions that ultimately culminate in vascular wall
destruction.
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